Botulinum Toxin Treatment in Patients with Facial Synkinesis

Laskawi, R.; Damenz, W.; Roggenkämper, P; Baetz, A.

doi:10.1007/978-3-642-85090-5_70

Cited by 14 publications

(24 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study demonstrated the efficacy of BT‐A in the treatment of both postparetic synkinesis and hyperkinesis, thus confirming literature findings 1, 2, 4–6. Most of the studies available focus on synkinesis.…”

Section: Discussionsupporting

confidence: 88%

“…Initially, these methods were developed to treat facial palsy and not to ameliorate synkinesis or hyperkinesis. For many years, botulinum toxin (BT) chemical neurectomy was considered a good approach in treating these conditions 2, 4, 5. BT is a protein derived from a bacterium ( Clostridium botulinum ), and is present in seven serologic types, including A, B, C, D, E, F, and G 6–8.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum toxin in the treatment of facial synkinesis and hyperkinesis

et al. 2012

View full text Add to dashboard Cite

This work stresses the importance of considering synkinesis and hyperkinesis separately because they are different conditions. These two symptoms showed improvement after botulinum toxin treatment, but only hyperkinesis showed a positive correlation when objective and subjective evaluations were performed. This treatment is effective in the management of facial synkinesis and hyperkinesis due to facial palsy, thus improving quality of life. It is a safe, minimally invasive treatment that can be repeated.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Botulinum toxin in the treatment of facial synkinesis and hyperkinesis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Clinical-functional evaluation was performed both before the treatment (on the same day) and after a median of 18 days (interquartile ranges [IQR] [14][15][16][17][18][19][20][21][22][23] At each assessment, a global facial function evaluation was performed with the Italian version of the Sunnybrook Facial Grading System (SFGS). 29 The scale is comprised of three specific sections with partial scores (resting symmetry: from 220 to 0; symmetry of voluntary movement: 20 to 100; synkinesis associated with five specified voluntary movements: 215 to 0) and a composite score ranging from 0 (5 complete palsy) to 100 (5 normal facial function).…”

Section: Clinical Evaluationmentioning

confidence: 99%

Platysma synkinesis in facial palsy and botulinum toxin type A

Dall'Angelo¹,

Mandrini²,

Sala³

et al. 2014

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…Its objective is to relieve compensating muscle overactivity on the healthy side (hypertonia) while reducing spasms and synkinesis on the paralyzed side in order to obtain facial symmetry at rest and during facial expressions. The relevance of botulinum toxin in clinical improvement has been demonstrated in several studies [3][4][5][6][7][8][9][10], providing a better quality of life for these patients [8,11]. Techniques and injection sites were already described many times over [4,7,8,10].…”

Section: Introductionmentioning

confidence: 95%